Group 1 - The article discusses the trend of fund managers transitioning to roles as company secretaries in listed companies, indicating a shift beyond asset management [1][4] - Jiang Ying has been appointed as the new company secretary of Luoxin Pharmaceutical, marking a notable case of a fund manager moving into this role [2][3] - Jiang Ying has a strong academic background with dual degrees in Science and Economics from Peking University, and a Master's in Management and Finance from Hong Kong University, but lacks prior experience as a company secretary [3] Group 2 - Luoxin Pharmaceutical reported a revenue of 1.077 billion yuan for the first half of 2025, a year-on-year decrease of 14.45%, while achieving a net profit of 17.695 million yuan, indicating a turnaround from losses in the previous year [4] - The company has faced significant performance fluctuations in recent years, attributed to factors such as the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [4] - The trend of hiring former financial professionals as company secretaries has been noted, with examples including Wang Shangbo from Hongtu Innovation Fund and Liu Haoyu from Dongwu Fund, who have transitioned to roles in listed companies [4]

Core Viewpoint - The trend of fund managers transitioning to roles as company secretaries in listed firms is increasing, indicating a shift beyond traditional asset management roles [2][6]. Group 1: Fund Manager Transition - More fund managers are being appointed as company secretaries in listed companies, a trend that has been observed since 2024 [2][6]. - The case of Jiang Ying, a former fund manager at Guotai Fund, being appointed as the secretary of Luoxin Pharmaceutical highlights this trend [3][6]. - Jiang Ying has a strong academic background with degrees from Peking University and the University of Hong Kong, but lacks prior experience as a company secretary [3][6]. Group 2: Company Performance - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields, but has faced significant performance fluctuations in recent years [6]. - The company reported a revenue of 1.077 billion yuan for the first half of 2025, a decrease of 14.45% year-on-year, while achieving a net profit of 17.695 million yuan, marking a return to profitability [6][7]. - The financial performance of Luoxin Pharmaceutical has been impacted by factors such as the COVID-19 pandemic and adjustments in financial liabilities [6][7]. Group 3: Broader Industry Trends - The trend of financial professionals moving into corporate roles is not limited to fund managers; there are also instances of analysts and investment bankers transitioning to company secretary positions [8][9]. - The hiring of former fund managers for roles in research and development within companies, such as Liu Haoyu at Donghua Energy, indicates a diversification of career paths for financial professionals [9].